Cargando…

Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation

Atrial fibrillation (AF) is associated with significant risk of stroke and other thromboembolic events, which can be effectively prevented using oral anticoagulation (OAC) with either vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, or edoxaban....

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueberham, Laura, Dagres, Nikolaos, Potpara, Tatjana S., Bollmann, Andreas, Hindricks, Gerhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656712/ https://www.ncbi.nlm.nih.gov/pubmed/28956288 http://dx.doi.org/10.1007/s12325-017-0616-6

Ejemplares similares

Initial rivaroxaban dosing in patients with atrial fibrillation
por: Ablefoni, Kaja, et al.
Publicado: (2019)

Non-Pharmacological Stroke Prevention in Atrial Fibrillation
por: Anduaga, Iñigo, et al.
Publicado: (2023)

Association of atrial fibrillation susceptibility genes, atrial fibrillation phenotypes and response to catheter ablation: a gene-based analysis of GWAS data
por: Husser, Daniela, et al.
Publicado: (2017)

Association between PR interval prolongation and electro-anatomical substrate in patients with atrial fibrillation
por: Schumacher, Katja, et al.
Publicado: (2018)

Is epicardial fat tissue associated with atrial fibrillation recurrence after ablation? A systematic review and meta-analysis
por: Sepehri Shamloo, Alireza, et al.
Publicado: (2019)

Rate of acquired pulmonary vein stenosis after ablation of atrial fibrillation referred to electroanatomical mapping systems: Does it matter?
por: Schoene, Katharina, et al.
Publicado: (2019)

Characteristics of left atrial remodeling in patients with atrial fibrillation and hypertrophic cardiomyopathy in comparison to patients without hypertrophy
por: Nedios, Sotirios, et al.
Publicado: (2021)

Genomic Contributors to Rhythm Outcome of Atrial Fibrillation Catheter Ablation – Pathway Enrichment Analysis of GWAS Data
por: Husser, Daniela, et al.
Publicado: (2016)

Sleep Disorders and Atrial Fibrillation: Current Situation and Future Directions
por: Sepehri Shamloo, Alireza, et al.
Publicado: (2018)

Exercise and Atrial Fibrillation: Some Good News and Some Bad News
por: Sepehri Shamloo, Alireza, et al.
Publicado: (2018)

Galectin-3 in Patients with Atrial Fibrillation Undergoing Radiofrequency Catheter Ablation
por: Kornej, Jelena, et al.
Publicado: (2015)

Predictors of rhythm outcomes after cardiac resynchronization therapy in atrial fibrillation patients: When should we use an atrial lead?
por: Nedios, Sotirios, et al.
Publicado: (2020)

PR Interval Associated Genes, Atrial Remodeling and Rhythm Outcome of Catheter Ablation of Atrial Fibrillation—A Gene-Based Analysis of GWAS Data
por: Husser, Daniela, et al.
Publicado: (2017)

Genomic contributors to atrial electroanatomical remodeling and atrial fibrillation progression: Pathway enrichment analysis of GWAS data
por: Husser, Daniela, et al.
Publicado: (2016)

Identification of Central Regulators of Calcium Signaling and ECM–Receptor Interaction Genetically Associated With the Progression and Recurrence of Atrial Fibrillation
por: Büttner, Petra, et al.
Publicado: (2018)

Update on the Non-Pharmacological Management of Stroke Prevention in Patients with Atrial Fibrillation
por: Tolat, Aneesh, et al.
Publicado: (2018)

Association Between Cardiovascular Magnetic Resonance‐Derived Left Atrial Dimensions, Electroanatomical Substrate and NT‐proANP Levels in Atrial Fibrillation
por: Seewöster, Timm, et al.
Publicado: (2018)

Non-pharmacological Treatment of Atrial Fibrillation
por: Anfinsen, Ole-Gunnar
Publicado: (2002)

Flecainide-Associated Cardiogenic Shock in a Patient with Atrial Fibrillation
por: Gjermeni, Erind, et al.
Publicado: (2019)

P-wave duration and atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis
por: Intzes, Stergios, et al.
Publicado: (2022)

Stroke prevention in atrial fibrillation: comparison of recent international guidelines
por: Chao, Tze-Fan, et al.
Publicado: (2020)

Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor
por: Potpara, Tatjana S., et al.
Publicado: (2016)

Editorial: Mechanism and prevention of atrial fibrillation
por: Li, Guowei, et al.
Publicado: (2022)

C-kit(pos) cells in the human left atrial appendage
por: Schwarzkopf, Lea, et al.
Publicado: (2023)

Patients’ attitude towards a sham-controlled trial on pulmonary vein isolation in atrial fibrillation
por: Uhe, Tobias, et al.
Publicado: (2021)

Rare variants in genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation of atrial fibrillation
por: Husser, Daniela, et al.
Publicado: (2017)

Subject-Specific Calculation of Left Atrial Appendage Blood-Borne Particle Residence Time Distribution in Atrial Fibrillation
por: Sanatkhani, Soroosh, et al.
Publicado: (2021)

Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal
por: Lip, Gregory Y H, et al.
Publicado: (2023)

Computed tomography model-based treatment of atrial fibrillation and atrial macro-re-entrant tachycardia
por: Piorkowski, Christopher, et al.
Publicado: (2008)

Network Pharmacology and Pharmacological Mechanism of CV-3 in Atrial Fibrillation
por: Wang, Zundong, et al.
Publicado: (2022)

The APPLE Score – A Novel Score for the Prediction of Rhythm Outcomes after Repeat Catheter Ablation of Atrial Fibrillation
por: Kornej, Jelena, et al.
Publicado: (2017)

Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation
por: Lee, Vivian Wing-Yan, et al.
Publicado: (2016)

Optimal Choice of Pharmacological Therapy – Prevention of Stroke and Assessment of Bleeding Risk in Patients with Atrial Fibrillation
por: Hodzic, Enisa, et al.
Publicado: (2019)

Limitations in Contemporary Pharmacological Stroke Prevention Therapies in Atrial Fibrillation: A Descriptive Literature Review
por: Garot, Philippe, et al.
Publicado: (2023)

Non-Pharmacological Therapy for Atrial Fibrillation: Managing the Left Atrial Appendage
por: Luis, Sushil Allen, et al.
Publicado: (2012)

Stroke, Dementia, and Atrial Fibrillation: From Pathophysiologic Association to Pharmacological Implications
por: Russo, Vincenzo, et al.
Publicado: (2020)

Pharmacological cardioversion for atrial fibrillation and flutter
por: Cordina, J, et al.
Publicado: (2006)

Clinical Pharmacology of Chronic Atrial Fibrillation
por: Lewis, Richard, et al.
Publicado: (1988)

Non-Pharmacologic Approach to Prevent Embolization in Patients with Atrial Fibrillation in Whom Anticoagulation is Contraindicated
por: Sharma, Munish, et al.
Publicado: (2017)

Outcome of pharmacological treatment of patients with atrial fibrillation in the emergency room
por: Ivekovic, H, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_t6b35omt2hbci63l484mseguv1